BACKGROUND: Ending homelessness is a major priority of the Department of Veteran Affairs (VA), and alcohol use can be a barrier to stable housing. Clinical trials suggest that depot extended-release naltrexone (XR-NTX) is efficacious in reducing alcohol consumption among alcohol-dependent subjects. METHODS: An open-label, randomized pilot study sought to examine the feasibility and effectiveness of XR-NTX versus oral naltrexone to improve alcohol consumption and housing stability among homeless, alcohol-dependent veterans at the Providence Veteran Affairs Medical Center. RESULTS:Of 215 potential candidates approached over a 16-month recruitment period, only 15 agreed to consider study entry and 7 were randomized. The primary reasons given for refusal were not wanting an injection; fear of needles; and not wanting to change drinking habits. Only 1 participant in the XR-NTX group returned after the first injection. Three participants in the oral naltrexone group attended all 7 visits and had good outcomes. CONCLUSIONS: Although XR-NTX has demonstrated efficacy in reducing heavy drinking, limited acceptance of the injection might reduce its effectiveness among homeless, alcohol-dependent patients.
RCT Entities:
BACKGROUND: Ending homelessness is a major priority of the Department of Veteran Affairs (VA), and alcohol use can be a barrier to stable housing. Clinical trials suggest that depot extended-release naltrexone (XR-NTX) is efficacious in reducing alcohol consumption among alcohol-dependent subjects. METHODS: An open-label, randomized pilot study sought to examine the feasibility and effectiveness of XR-NTX versus oral naltrexone to improve alcohol consumption and housing stability among homeless, alcohol-dependent veterans at the Providence Veteran Affairs Medical Center. RESULTS: Of 215 potential candidates approached over a 16-month recruitment period, only 15 agreed to consider study entry and 7 were randomized. The primary reasons given for refusal were not wanting an injection; fear of needles; and not wanting to change drinking habits. Only 1 participant in the XR-NTX group returned after the first injection. Three participants in the oral naltrexone group attended all 7 visits and had good outcomes. CONCLUSIONS: Although XR-NTX has demonstrated efficacy in reducing heavy drinking, limited acceptance of the injection might reduce its effectiveness among homeless, alcohol-dependent patients.
Authors: Thomas P O'Toole; Alicia Conde-Martel; Jeanette L Gibbon; Barbara H Hanusa; Michael J Fine Journal: J Gen Intern Med Date: 2003-11 Impact factor: 5.128
Authors: James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich Journal: JAMA Date: 2005-04-06 Impact factor: 56.272
Authors: Thomas P O'Toole; Lauren Buckel; Claire Bourgault; Jonathan Blumen; Stephen G Redihan; Lan Jiang; Peter Friedmann Journal: Am J Public Health Date: 2010-10-21 Impact factor: 9.308
Authors: Erin J Stringfellow; Theresa W Kim; Adam J Gordon; David E Pollio; Richard A Grucza; Erika L Austin; N Kay Johnson; Stefan G Kertesz Journal: Subst Abus Date: 2016-02-25 Impact factor: 3.716
Authors: Susan E Collins; Andrew J Saxon; Mark H Duncan; Brian F Smart; Joseph O Merrill; Daniel K Malone; T Ron Jackson; Seema L Clifasefi; Jutta Joesch; Richard K Ries Journal: Contemp Clin Trials Date: 2014-05-17 Impact factor: 2.226
Authors: Shan-Estelle Brown; Panagiotis Vagenas; Kelika A Konda; Jesse L Clark; Javier R Lama; Pedro Gonzales; Jorge Sanchez; Ann C Duerr; Frederick L Altice Journal: Am J Mens Health Date: 2015-03-17
Authors: A-L Wang; I Elman; S B Lowen; S J Blady; K G Lynch; J M Hyatt; C P O'Brien; D D Langleben Journal: Transl Psychiatry Date: 2015-03-17 Impact factor: 6.222